Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom Broadcom ... In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo JMP Securities initiates coverage on Summit ...
Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...
Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...
IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...
Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...
Coherus (CHRS) stock rallied 19% Thursday, the day after the company reported higher-than-expected Q3 revenue and said it had ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
AlloVir (ALVR) stock falls as comany agrees to an all-stock merger transaction with Kalaris Therapeutics. Read more here.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Liberty Media Corp. Series C Liberty Formula One-0.55% $24.59B Liberty Media Corp. Series A Liberty Formula One-0.44% $24.59B Liberty Broadband Corp. Cl A-1.04% $14.07B Liberty Broadband Corp. Cl ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback